FDA Deputy Director of Regulatory Programs Doug Throckmorton assured lawmakers during a recent hearing that the agency doesn’t need more authority from Congress to regulate cannabidiol (CBD) products. What the agency needs is more data to better understand the risks of using CBD, he said. Members of Congress grilled the FDA official about the agency’s plans to issue CBD regulations, but one key lawmaker argued Throckmorton was being evasive. Throckmorton said he thinks it’s “terribly important” the agency lay out...